U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07188480) titled 'The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients' on Sept. 10.
Brief Summary: Patients with advanced non-small cell lung cancer (NSCLC) usually undergo biopsies to obtain cytological material on which to perform Next Generation Sequencing (NGS) analysis, with the aim of identifying driver gene mutations that may be targeted by specific therapies. With the development of drugs with specific therapeutic targets, the clinical need for re-biopsy or even repeated biopsies is increasing; these biopsies are necessary to identify the mechanisms of drug resistance in the target lesions. Very often, lung cancer presen...